Semaglutide: The GLP-1 That Changed the Conversation Around Weight Loss

Semaglutide is not a research chemical in the same way most compounds discussed on this site are. It's a fully approved pharmaceutical — licensed for type 2 diabetes as Ozempic, and for chronic weight management as Wegovy. It has gone through the full clinical trial process, has robust safety data from large human studies, and is now one of the most prescribed drugs on the planet. That's worth stating clearly before going into the mechanism.

What GLP-1 Is

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It does several things: it signals the pancreas to release insulin in response to rising blood glucose, it suppresses glucagon (which would otherwise raise blood glucose), it slows gastric emptying so food is digested more gradually, and — critically — it acts on receptors in the brain to reduce appetite. The brain piece is what makes GLP-1 agonists so powerful as weight loss agents.

Natural GLP-1 has a half-life of about two minutes in the bloodstream before an enzyme called DPP-4 breaks it down. Semaglutide is engineered to resist that breakdown — it has a half-life of approximately a week, which is why it's injected once weekly rather than continuously.

The Clinical Data

The STEP trials — a series of phase 3 clinical studies published in the New England Journal of Medicine and other journals between 2021 and 2023 — are what put semaglutide on the map for weight management. In STEP 1, participants without diabetes lost an average of 14.9% of their body weight over 68 weeks on 2.4mg weekly semaglutide, compared to 2.4% in the placebo group. Roughly a third of participants lost 20% or more of their body weight.

These are numbers the weight loss pharmaceutical industry had never seen before. The best previous drug, orlistat, achieved around 3% greater weight loss than placebo. The obesity medicine community essentially had to update its understanding of what was pharmacologically possible.

The SELECT trial, published in 2023, added an important dimension: in people with pre-existing cardiovascular disease, semaglutide reduced the rate of major adverse cardiac events (heart attacks, strokes, cardiovascular death) by 20% compared to placebo. This shifted semaglutide from a weight loss drug to a potential cardiovascular medicine — a significant distinction.

How It Produces Weight Loss

The primary mechanism is appetite suppression through central nervous system effects. Semaglutide binds to GLP-1 receptors in the hypothalamus and brainstem — areas involved in hunger regulation — and reduces appetite in a way that many users describe as qualitatively different from willpower-based restriction. The food noise, as people call it, quietens.

Gastric emptying slows significantly, which means you feel full sooner and for longer after eating. Insulin sensitivity may improve independently of weight loss. Some research suggests effects on reward pathways that reduce cravings for high-calorie foods specifically, though this is less established.

The weight loss is real and it is significant. It is also, largely, maintained only for as long as the drug is taken. The STEP 4 trial showed that participants who stopped semaglutide after 20 weeks of treatment regained about two-thirds of their lost weight over the subsequent year. This is not a failure of the drug — it reflects the fact that semaglutide treats a chronic condition, not a temporary one. The implication is that for many people, this is a long-term or permanent medication rather than a course treatment.

Side Effects

Nausea is the most common side effect, experienced by roughly 40% of patients, and is most pronounced during dose escalation. It typically improves over time. Vomiting, diarrhoea, and constipation are also reported. Starting at a low dose (0.25mg weekly) and titrating slowly — the standard protocol — significantly reduces the severity of GI side effects for most people.

More serious reported adverse events include pancreatitis (rare), gallbladder problems (more common with rapid weight loss generally, not necessarily semaglutide specifically), and, controversially, thyroid C-cell tumours — this was observed in rodent studies and is a black box warning, though the relevance to humans at clinical doses remains a matter of scientific debate.

There has also been emerging discussion about muscle mass loss during semaglutide-driven weight reduction. Rapid weight loss by any mechanism tends to include some lean mass loss, and several studies suggest this proportion may be higher with GLP-1 agonists than with caloric restriction alone. Resistance training and adequate protein intake appear to mitigate this, but it's something people should be aware of rather than ignoring.

Compounded Semaglutide

The global shortage of branded semaglutide products created a market for compounded versions — semaglutide produced by compounding pharmacies and sold at a fraction of the brand price. In the UK and US, this has been a significant grey area. Compounded products are not subject to the same manufacturing standards as pharmaceutical-grade drugs, and quality varies considerably. The shortage has now largely resolved in many markets, and regulatory bodies have been tightening the rules around compounding accordingly.

The Wider Context

Semaglutide represents the first genuinely effective pharmacological treatment for obesity that most clinicians consider safe enough for broad use. Tirzepatide (Mounjaro), which adds a GIP receptor agonist to the GLP-1 mechanism, has shown even larger weight loss effects in trials. The next generation of compounds in this class is already in phase 3 trials.

What this means practically is that the "obesity is a personal failing" conversation is becoming harder to sustain as the biological mechanisms become better understood and better treated. Whether that's a welcome development or an uncomfortable one probably depends on who you ask.